Clinical Trials
Experiencing Thinning at the Crown?
We’re recruiting for a Phase III clinical trial in Canada for TH07, our topical spray treatment for hair loss. Check the criteria below and apply today to help bring an innovative product to market that will change the lives of millions of people.
The Phase III clinical trial (NCT07435012) is designed to evaluate the safety and efficacy of TH07 in men with androgenic alopecia. TH07 is a topical spray product that combines three active ingredients, minoxidil, finasteride, and latanoprost, each of which has demonstrated relevance to hair-growth biology through approved use and published scientific literature.
This 24-week, randomized, triple-blind, placebo-controlled, multicentre research study is expected to enroll 420 male participants with moderate to moderately advanced androgenic alopecia across up to 10 clinical sites in Canada.
Protocol Summary
The Triple Hair team is recruiting for a Phase III clinical trial in Canada for TH07, our topical spray product for hair loss. The research study will evaluate how well TH07 improves hair density compared with a gold-standard medication and a placebo.
Do you qualify?
The final Phase 3 clinical trial of a research study for hair growth is open for men.
Do you meet the following list of criteria?
Those who qualify and enroll in the study may receive the following at no cost
6-month investigational treatment or a placebo*
Professional scalp monitoring by doctors
Contribution to the future of hair science
*Placebo is a pill that looks like the study drug, but contains no active ingredients
Apply
Select your nearest clinic to complete a short eligibility questionnaire.
Vancouver, BC
Moncton, NB
Toronto, ON
Edmonton, AB
Coming Soon
Winnipeg, MN
Coming Soon
IRB Over-sighted
Health Canada Approved Trial
FAQs
A clinical trial is a research study where volunteers help test new medical treatments to determine if they are safe and effective. Participants who qualify receive study-related care under medical supervision, and participation is always voluntary.
Triple Hair Group Inc. is a Canadian biotechnology company focused on the development of innovative therapies for androgenic alopecia, a condition affecting hundreds of millions of men and women worldwide.
The global hair-loss treatment market was valued at approximately US$8.8 billion in 2023 and is projected to reach over US$16 billion by 2030, reflecting the significant demand for safe and effective treatment options.
The Phase III clinical trial (NCT07435012) is designed to evaluate the safety and efficacy of TH07 in men with androgenic alopecia. TH07 is a topical spray formulation that combines three active ingredients, minoxidil, finasteride, and latanoprost, each of which has demonstrated relevance to hair-growth biology through approved use and published scientific literature.
This 24-week, randomized, double-blind, placebo-controlled, multicentre study is expected to enroll 420 male participants with moderate to moderately advanced androgenic alopecia across up to 10 clinical sites in Canada.
TH07 is a triple-combination topical spray product that combines minoxidil, finasteride and latanoprost, three pharmacologically active agents that target distinct biological pathways involved in androgenic alopecia.
The therapy is designed to address multiple mechanisms associated with hair loss by:
- stimulating hair follicle activity,
- reducing androgen-mediated follicle miniaturization, and
- supporting prolonged hair growth cycles.
By integrating these complementary mechanisms in a single topical formulation, TH07 is designed to simultaneously target several key drivers of hair loss.
